Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Published:2016-11 Issue:11 Volume:3 Page:e506-e515
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

San-Miguel Jesús F,Hungria Vania T M,Yoon Sung-Soo,Beksac Meral,Dimopoulos Meletios A,Elghandour Ashraf,Jedrzejczak Wieslaw W,Günther Andreas,Nakorn Thanyaphong N,Siritanaratkul Noppadol,Schlossman Robert L,Hou Jian,Moreau Philippe,Lonial Sagar,Lee Jae H,Einsele Hermann,Sopala Monika,Bengoudifa Bourras-Rezki,Binlich Florence,Richardson Paul G

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

3. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

5. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells;Catley;Blood,2006

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological targeting of the cancer epigenome;Nature Cancer;2024-06-27

2. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

3. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

4. HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation;Cancer Research Communications;2024-02-09

5. Multiple Myeloma;Comprehensive Hematology and Stem Cell Research;2024